Ceribell - FloodGate Medical

Clarity When It's Critial

About Us

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. Our mission is to establish the Ceribell System as the standard of care for EEG in the acute care setting and help clinicians save patient lives.

Look at the Leaders of Ceribell

Jane Chao, PHD

CEO, Co-Founder, and Director

Raymond Woo, PHD

Chief Technology Officer

Scott Blumberg

Chief Financial Officer

Featured Services and Innovations

Point-of-Care EEG

Ceribell’s Point-of-Care EEG system is a portable, FDA-cleared electroencephalography platform designed to enable rapid, bedside brain monitoring in emergency and critical care settings. It empowers clinicians to initiate EEG assessments in under five minutes with minimal training, facilitating timely diagnosis and intervention for patients at risk of seizures. The system includes a disposable headband with integrated electrodes and a handheld recorder that provides real-time EEG data, which can be streamed to a cloud-based portal for remote review by neurologists. This streamlined approach supports confident clinical decisions, reduces unnecessary treatments, and improves patient outcomes by enabling early detection and management of seizure activity.

Clarity

Clarity, the Ceribell machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder, including automatic alerts in the event of non-convulsive status epilepticus.

EEG Portal

The Ceribell EEG Portal is a cloud-based platform that enhances the accessibility and efficiency of EEG monitoring in critical care settings. It allows healthcare providers to remotely review EEG data in real time, enabling timely and informed clinical decisions. The portal features an intuitive interface with sorting, filtering, and annotation tools to streamline EEG review, as well as a mobile-optimized version that includes Focus Mode for maximizing screen space. Additionally, it offers access to an expert-annotated EEG reference library to support clinical decision-making. By integrating the EEG Portal into clinical workflows, providers can improve diagnostic accuracy and patient outcomes in neurocritical care.

Provider Experiences with Ceribell

Paul

“Ceribell, is easy to use, easy to apply, and would be greatly utilized in emergency departments or small hospitals where they just don’t have the available services to rapidly assess the patient.”

Laleh

“They are eager to use it [Ceribell] because they understand its effect and impact and the data that they can obtain from it is quite easily and quite quickly and quite accurate.”

Emily

“The Ceribell EEG technologies have improved our ability to detect and treat seizures… it’s readily available, it’s in the ICU, it’s in the emergency department.”

Company Spotlight Video

News and Stories

Medtech Leader Erica Rogers Joins Ceribell Board of Directors

SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell’s Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting.

Ceribell Reports Second Quarter 2025 Financial Results

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025.

Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference

SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!